Tag: project

Findings from Phase 2 of the "Power of Play: Family Connection" study from Kinder and the University of East London (UEL) confirm that shared...

XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...

XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...

Automotive tier 2 zinc die-casting manufacturer adopts cloud-based MES, QMS, EDI and analytics to provide real-time visibility, traceability and quality across a new greenfield...

CANBERRA, Australia, June 11, 2026 /PRNewswire/ -- Seeing Machines Limited (AIM: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems...

MONACO, June 10, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after the project submitted its CoinGecko listing as launch preparations continue to move forward. The presale has now crossed $1.49 million in total capital raised, Stage 17 is live at $0.01877, and holder growth has passed 9,400 while AlphaSwap demo traction and audit completion continue to support the project’s pre-listing profile.

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

VANCOUVER, BC, June 11, 2026 /PRNewswire/ -- (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce...

VANCOUVER, BC, June 10, 2026 /CNW/ - (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce the...

CALGARY, AB, June 10, 2026 /CNW/ - The Clean Resource Innovation Network (CRIN) will fund 11 new innovative projects as part of the Accelerating...

TORONTO, June 10, 2026 /CNW/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...

TORONTO, June 10, 2026 /PRNewswire/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that shareholders of...

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./TORONTO, June 10, 2026 /CNW/ - Canada...